254 related articles for article (PubMed ID: 28153080)
21. Severe delayed skin reactions related to drugs in the paediatric age group: A review of the subject by way of three cases (Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS).
Belver MT; Michavila A; Bobolea I; Feito M; Bellón T; Quirce S
Allergol Immunopathol (Madr); 2016; 44(1):83-95. PubMed ID: 26089185
[TBL] [Abstract][Full Text] [Related]
22. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis.
Ririe MR; Blaylock RC; Morris SE; Jung JY
J Am Acad Dermatol; 2013 Aug; 69(2):221-5. PubMed ID: 23673282
[TBL] [Abstract][Full Text] [Related]
23. RF - Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Treatment Update.
de Quintana-Sancho A; Rubio-Lombraña M; Guergue Díaz-de-Cerio O; Barrutia-Borque A
Actas Dermosifiliogr; 2016 Apr; 107(3):247-8. PubMed ID: 26138285
[No Abstract] [Full Text] [Related]
24. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
[TBL] [Abstract][Full Text] [Related]
25. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016.
Creamer D; Walsh SA; Dziewulski P; Exton LS; Lee HY; Dart JKG; Setterfield J; Bunker CB; Ardern-Jones MR; Watson KMT; Wong GAE; Philippidou M; Vercueil A; Martin RV; Williams G; Shah M; Brown D; Williams P; Mohd Mustapa MF; Smith CH
J Plast Reconstr Aesthet Surg; 2016 Jun; 69(6):e119-e153. PubMed ID: 27287213
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological differential diagnosis of drug-induced toxic epidermal necrolysis (Lyell's syndrome) and acute graft-versus-host reaction.
Paquet P; Arrese JE; Beguin Y; Piérard GE
Curr Top Pathol; 2001; 94():49-63. PubMed ID: 11443887
[No Abstract] [Full Text] [Related]
27. Sulindac-induced Stevens-Johnson toxic epidermal necrolysis syndrome.
Levitt L; Pearson RW
JAMA; 1980 Mar; 243(12):1262-3. PubMed ID: 7359684
[No Abstract] [Full Text] [Related]
28. Renal disease associated with toxic epidermal necrolysis (Lyell's disease).
Krumlovsky FA; Del Greco F; Herdson PB; Lazar P
Am J Med; 1974 Nov; 57(5):817-25. PubMed ID: 4440703
[No Abstract] [Full Text] [Related]
29. [Severe skin reactions. Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema exsudativum multiforme majus and generalized bullous fixed drug exanthema].
Rzany B; Mockenhaupt M; Baur S; Stocker U; Schöpf E
Hautarzt; 1993 Aug; 44(8):549-54; quiz 554-6. PubMed ID: 8376113
[No Abstract] [Full Text] [Related]
30. Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome.
Lerner LH; Qureshi AA; Reddy BV; Lerner EA
J Invest Dermatol; 2000 Jan; 114(1):196-9. PubMed ID: 10620138
[TBL] [Abstract][Full Text] [Related]
31. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand.
Abe R; Shimizu T; Shibaki A; Nakamura H; Watanabe H; Shimizu H
Am J Pathol; 2003 May; 162(5):1515-20. PubMed ID: 12707034
[TBL] [Abstract][Full Text] [Related]
32. [Stevens-Johnson syndrome and toxic epidermal necrolysis following intake of sulfonamides].
Aberer W; Stingl G; Wolff K
Hautarzt; 1982 Sep; 33(9):484-90. PubMed ID: 7174320
[TBL] [Abstract][Full Text] [Related]
33. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review.
Wong A; Malvestiti AA; Hafner Mde F
Rev Assoc Med Bras (1992); 2016; 62(5):468-73. PubMed ID: 27656858
[TBL] [Abstract][Full Text] [Related]
34. Drug-induced toxic epidermal necrolysis.
Heng MC
Br J Dermatol; 1985 Nov; 113(5):597-600. PubMed ID: 4063192
[No Abstract] [Full Text] [Related]
35. Toxic epidermal necrolysis: examining a multifaceted enigma.
Binnick SA; Pirozzi DJ
Postgrad Med; 1975 Oct; 58(4):126-30. PubMed ID: 1099565
[No Abstract] [Full Text] [Related]
36. [Stevens-Johnson syndrome and toxic epidermal necrolysis; therapy policy in these life-threatening illnesses. Netherlands Work Group Toxic Epidermal Necrolysis].
van der Meer JB
Ned Tijdschr Geneeskd; 1996 Jul; 140(30):1538-43. PubMed ID: 8765761
[No Abstract] [Full Text] [Related]
37. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Tohyama M; Watanabe H; Murakami S; Shirakata Y; Sayama K; Iijima M; Hashimoto K
Br J Dermatol; 2012 Feb; 166(2):322-30. PubMed ID: 21936856
[TBL] [Abstract][Full Text] [Related]
38. High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome.
Nakajima S; Watanabe H; Tohyama M; Sugita K; Iijima M; Hashimoto K; Tokura Y; Nishimura Y; Doi H; Tanioka M; Miyachi Y; Kabashima K
Arch Dermatol; 2011 Sep; 147(9):1110-2. PubMed ID: 21931056
[No Abstract] [Full Text] [Related]
39. [Stevens-Johnson Syndrom and Toxic Epidermal Necrolysis--based on literature].
Łoboda J; Dudzik A; Chomyszyn-Gajewska M
Przegl Lek; 2015; 72(1):35-7. PubMed ID: 26076576
[TBL] [Abstract][Full Text] [Related]
40. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.
Bastuji-Garin S; Rzany B; Stern RS; Shear NH; Naldi L; Roujeau JC
Arch Dermatol; 1993 Jan; 129(1):92-6. PubMed ID: 8420497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
